703 related articles for article (PubMed ID: 17290056)
21. Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML.
Nevill TJ; Hogge DE; Toze CL; Nantel SH; Power MM; Abou Mourad YR; Song KW; Lavoie JC; Forrest DL; Barnett MJ; Shepherd JD; Nitta JY; Wong S; Sutherland HJ; Smith CA
Bone Marrow Transplant; 2008 Nov; 42(10):659-66. PubMed ID: 18679372
[TBL] [Abstract][Full Text] [Related]
22. Chromosomal abnormalities in secondary MDS and AML. Relationship to drugs and radiation with specific emphasis on the balanced rearrangements.
Andersen MK; Johansson B; Larsen SO; Pedersen-Bjergaard J
Haematologica; 1998 Jun; 83(6):483-8. PubMed ID: 9676019
[TBL] [Abstract][Full Text] [Related]
23. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.
Engert A; Diehl V; Franklin J; Lohri A; Dörken B; Ludwig WD; Koch P; Hänel M; Pfreundschuh M; Wilhelm M; Trümper L; Aulitzky WE; Bentz M; Rummel M; Sezer O; Müller-Hermelink HK; Hasenclever D; Löffler M
J Clin Oncol; 2009 Sep; 27(27):4548-54. PubMed ID: 19704068
[TBL] [Abstract][Full Text] [Related]
24. Secondary or concomitant neoplasms among adults diagnosed with acute lymphoblastic leukemia and treated according to the LALA-87 and LALA-94 trials.
Tavernier E; Le QH; de Botton S; Dhédin N; Bulabois CE; Reman O; Vey N; Lhéritier V; Dombret H; Thomas X
Cancer; 2007 Dec; 110(12):2747-55. PubMed ID: 17963265
[TBL] [Abstract][Full Text] [Related]
25. Secondary malignancies in a child with Hodgkin's disease: T-cell lymphoma and myelodysplastic syndrome evolving into acute nonlymphoblastic leukaemia.
Polychronopoulou S; Panagiotou JP; Papadakis T; Mavrou A; Anagnostou D; Haidas S
Med Pediatr Oncol; 1996 May; 26(5):359-66. PubMed ID: 8614370
[TBL] [Abstract][Full Text] [Related]
26. Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma.
Howe R; Micallef IN; Inwards DJ; Ansell SM; Dewald GW; Dispenzieri A; Gastineau DA; Gertz MA; Geyer SM; Hanson CA; Lacy MQ; Tefferi A; Litzow MR
Bone Marrow Transplant; 2003 Aug; 32(3):317-24. PubMed ID: 12858205
[TBL] [Abstract][Full Text] [Related]
27. Second malignancy following high-dose therapy and autologous stem cell transplantation: incidence and risk factor analysis.
Forrest DL; Nevill TJ; Naiman SC; Le A; Brockington DA; Barnett MJ; Lavoie JC; Nantel SH; Song KW; Shepherd JD; Sutherland HJ; Toze CL; Davis JH; Hogge DE
Bone Marrow Transplant; 2003 Nov; 32(9):915-23. PubMed ID: 14561993
[TBL] [Abstract][Full Text] [Related]
28. Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up.
Brusamolino E; Baio A; Orlandi E; Arcaini L; Passamonti F; Griva V; Casagrande W; Pascutto C; Franchini P; Lazzarino M
Clin Cancer Res; 2006 Nov; 12(21):6487-93. PubMed ID: 17085663
[TBL] [Abstract][Full Text] [Related]
29. Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis.
Scholz M; Engert A; Franklin J; Josting A; Diehl V; Hasenclever D; Loeffler M
Ann Oncol; 2011 Mar; 22(3):681-688. PubMed ID: 20720088
[TBL] [Abstract][Full Text] [Related]
30. Second malignant neoplasms following childhood Hodgkin's disease: treatment and splenectomy as risk factors.
Meadows AT; Obringer AC; Marrero O; Oberlin O; Robison L; Fossati-Bellani F; Green D; Voûte PA; Morris-Jones P; Greenberg M
Med Pediatr Oncol; 1989; 17(6):477-84. PubMed ID: 2586362
[TBL] [Abstract][Full Text] [Related]
31. High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure.
Pedersen-Bjergaard J; Pedersen M; Myhre J; Geisler C
Leukemia; 1997 Oct; 11(10):1654-60. PubMed ID: 9324285
[TBL] [Abstract][Full Text] [Related]
32. Survival and late effects in children with Hodgkin's lymphoma treated with MOPP/ABV and low-dose, extended-field irradiation.
Chow LM; Nathan PC; Hodgson DC; Jenkin D; Weitzman S; Grant RM; Manson D; Bross A; Doyle JJ; Danjoux C; Greenberg ML
J Clin Oncol; 2006 Dec; 24(36):5735-41. PubMed ID: 17179107
[TBL] [Abstract][Full Text] [Related]
33. Second malignancies in young children with primary brain tumors following treatment with prolonged postoperative chemotherapy and delayed irradiation: a Pediatric Oncology Group study.
Duffner PK; Krischer JP; Horowitz ME; Cohen ME; Burger PC; Friedman HS; Kun LE
Ann Neurol; 1998 Sep; 44(3):313-6. PubMed ID: 9749596
[TBL] [Abstract][Full Text] [Related]
34. Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease.
Donaldson SS; Link MP; Weinstein HJ; Rai SN; Brain S; Billett AL; Hurwitz CA; Krasin M; Kun LE; Marcus KC; Tarbell NJ; Young JA; Hudson MM
J Clin Oncol; 2007 Jan; 25(3):332-7. PubMed ID: 17235049
[TBL] [Abstract][Full Text] [Related]
35. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs.
Leleu X; Soumerai J; Roccaro A; Hatjiharissi E; Hunter ZR; Manning R; Ciccarelli BT; Sacco A; Ioakimidis L; Adamia S; Moreau AS; Patterson CJ; Ghobrial IM; Treon SP
J Clin Oncol; 2009 Jan; 27(2):250-5. PubMed ID: 19064987
[TBL] [Abstract][Full Text] [Related]
36. Leukemia incidence following primary breast carcinoma treatment.
Kaplan HG; Malmgren JA; Atwood M
Cancer; 2004 Oct; 101(7):1529-36. PubMed ID: 15378478
[TBL] [Abstract][Full Text] [Related]
37. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011.
Morrison VA; Rai KR; Peterson BL; Kolitz JE; Elias L; Appelbaum FR; Hines JD; Shepherd L; Larson RA; Schiffer CA
J Clin Oncol; 2002 Sep; 20(18):3878-84. PubMed ID: 12228208
[TBL] [Abstract][Full Text] [Related]
38. Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series.
Pedersen-Bjergaard J; Philip P; Larsen SO; Andersson M; Daugaard G; Ersbøll J; Hansen SW; Hou-Jensen K; Nielsen D; Sigsgaard TC
Leukemia; 1993 Dec; 7(12):1975-86. PubMed ID: 8255096
[TBL] [Abstract][Full Text] [Related]
39. Incidence and susceptibility to therapy-related myeloid neoplasms.
Leone G; Fianchi L; Pagano L; Voso MT
Chem Biol Interact; 2010 Mar; 184(1-2):39-45. PubMed ID: 20026017
[TBL] [Abstract][Full Text] [Related]
40. Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies.
Kollmannsberger C; Hartmann JT; Kanz L; Bokemeyer C
J Cancer Res Clin Oncol; 1998; 124(3-4):207-14. PubMed ID: 9619748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
